Last updated: April 23, 2026
What does CN101980698 cover and how broad is its claimed subject matter?
CN101980698 is a Chinese patent application grant in the drug space. Without the full published patent text (title, abstract, claims, and description) and without claim-by-claim reading, the scope and enforceable claim boundaries cannot be determined accurately. Scope depends on (1) the independent claim categories, (2) defined chemical structures or Markush options, (3) functional language (if any), (4) dependent-claim narrowing, and (5) claim support in the specification.
Because this request requires a “scope and claims and patent landscape” analysis, producing a complete and accurate claim-scope map is not possible from the identifier alone.
What are the independent and dependent claims in CN101980698?
A claim-scope analysis requires the exact claim set as published in CN101980698, including:
- claim numbering
- the precise wording of independent claims
- Markush definitions and ranges (if present)
- definitions of compounds, salts, solvates, hydrates, polymorphs, and formulations (if present)
- method-of-treatment language and any dosing/administration limitations
- any examples used to establish enablement and breadth
That claim text is not available in the information provided here, so the independent/dependent structure and enforceable boundaries cannot be extracted.
How does CN101980698 typically interact with China patent law on drug inventions?
For China drug patents, landscape analysis normally hinges on:
- Claim construction by categories (compound, composition, method)
- Entitlement to priority and whether earlier foreign filings exist
- Prior art in China for novelty and inventive step
- Linkage to regulatory filings (where applicable) and the scope of IP protections
- Potential invalidity vectors: lack of unity, insufficient disclosure, and non-patentable subject matter where relevant
But applying these factors to CN101980698 requires the actual content of the claims and the patent’s cited documents and prosecution history.
What is the China patent landscape around CN101980698 (family, key competitors, and likely claim overlaps)?
A usable landscape for a specific CN patent requires, at minimum:
- the CN publication family members (priority application, counterpart jurisdictions, continuation/divisional equivalents if any)
- the status of relevant CN family members (granted vs withdrawn)
- related Chinese patents from the same assignee and from competitors
- citation and freedom-to-operate (FTO) mapping to identify overlapping chemical series, salts/polymorphs, and formulation claims
- alignment with the relevant Chinese indication and regulatory dossier timing
None of these can be produced from “CN101980698” alone without the publication record and full text.
Claim-scope map: what would be produced if the claim text were available?
A complete analysis for investors or R&D teams normally includes a structured claim map such as:
-
Independent Claim 1 (Compound/Formula/Genus claim)
- Core structural scaffold or generic formula
- Defined substituents and allowed variations
- Any explicit exclusions
- Salt/solvate/prodrug coverage if drafted as alternatives
- Breadth score based on number of allowed substituent combinations
-
Independent Claim 2 (Composition/Formulation)
- Active ingredient definition linking back to Claim 1
- Dosage form restrictions (tablet, capsule, injection)
- Excipient limitations (if any)
- Process limitations (if present)
-
Independent Claim 3 (Method of Treatment)
- Indication scope (disease class and patient population)
- Treatment regimen limitations (dose range, frequency)
- Administration route
- Co-therapy features (if any)
-
Dependent claims
- narrowing to preferred embodiments (specific substitutions, specific salts)
- polymorph or particle size definitions (if present)
- preferred dosage or stability conditions
- example compounds used to support enablement
This structure cannot be populated without the actual claim text.
Practical enforcement and risk points (normally derived from claim language)
For drug patents in China, enforcement risk typically turns on:
- Whether the main protection is a Markush genus or a specific compound
- Whether salts/polymorphs are explicitly covered
- Whether the method claims are limited enough to avoid easy design-around
- Whether dependent claims carry separate fallback embodiments that sustain validity if the broad claim is narrowed
- Whether the specification supports the full breadth (enablement for chemical genus claims)
These risk points must be tied to the exact wording of CN101980698 claims to be credible.
Key Takeaways
- A complete and accurate “scope and claims and patent landscape” analysis for CN101980698 cannot be produced from the identifier alone.
- The analysis requires the published claim set and the patent family and citation record to map enforceable boundaries and overlaps.
- Without claim text and landscape documents, any attempt to describe scope or competitors would be non-actionable for high-stakes R&D or investment decisions.
FAQs
1) Does CN101980698 likely claim a compound, composition, or method?
Not determinable without the published claims.
2) Is CN101980698 broad enough to cover salts/polymorphs and formulation variants?
Not determinable without the claim wording.
3) Which competitor patents most overlap with CN101980698?
Not determinable without assignee, family, and citation records.
4) Is CN101980698 still in force in China?
Not determinable without grant status and any legal status events.
5) What is the most common design-around strategy for patents like CN101980698?
Cannot be stated for this specific patent without its claim categories and defining limitations.
References
[1] CNIPA. Patent documents database (CN101980698).
